In vivo experiments also demonstrated that survivin ROP vaccination elicited robust CD4+ and CD8+ T cell immune responses and prolonged survival compared to the native survivin protein in a survivin-expressing melanoma mouse model.19 This evidence concerns the gene BIRC5 and melanoma.